Search Results - "Nout, R."

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy by Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.

“…Background PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT)…”
Get full text

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial by Nout, RA, Dr, Smit, VTHBM, MD, Putter, H, PhD, Jürgenliemk-Schulz, IM, MD, Jobsen, JJ, MD, Lutgens, LCHW, MD, van der Steen-Banasik, EM, MD, Mens, JWM, MD, Slot, A, MD, Kroese, MC Stenfert, MD, van Bunningen, BNFM, MD, Ansink, AC, MD, van Putten, WLJ, MSc, Creutzberg, CL, MD

“…Summary Background After surgery for intermediate-risk endometrial carcinoma, the vagina is the most frequent site of recurrence. This study established…”
Get full text

Practical guidance for mismatch repair-deficiency testing in endometrial cancer by Stelloo, E., Jansen, A.M.L., Osse, E.M., Nout, R.A., Creutzberg, C.L., Ruano, D., Church, D.N., Morreau, H., Smit, V.T.H.B.M., van Wezel, T., Bosse, T.

“…Mismatch repair (MMR)-deficiency analysis is increasingly recommended for all endometrial cancers, as it identifies Lynch syndrome patients, and is emerging as…”
Get full text

Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival by Bakker, S. H., Jacobs, W. C. H., Pondaag, W., Gelderblom, H., Nout, R. A., Dijkstra, P. D. S., Peul, W. C., Vleggeert-Lankamp, C. L. A.

“…Background and aims The aim of this systematic review is to describe the epidemiology of chordoma and to provide a clear overview of clinical prognostic…”
Get full text

L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results by Bosse, T, Nout, R.A, Stelloo, E, Dreef, E, Nijman, H.W, Jürgenliemk-Schulz, I.M, Jobsen, J.J, Creutzberg, C.L, Smit, V.T.H.B.M

“…Abstract Background L1 cell adhesion molecule (L1CAM) expression has been implicated as risk factor for disease recurrence in endometrial cancer (EC), most…”
Get full text

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial by Wortman, B.G., Bosse, T., Nout, R.A., Lutgens, L.C.H.W., van der Steen-Banasik, E.M., Westerveld, H., van den Berg, H., Slot, A., De Winter, K.A.J., Verhoeven-Adema, K.W., Smit, V.T.H.B.M., Creutzberg, C.L.

“…The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a randomized trial for women with high-intermediate risk endometrial cancer…”
Get full text

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial by Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, Melanie E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, Hans W., Smit, Vincent T.H.B.M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling, Horeweg, N., de Boer, S.M., Creutzberg, C.L., Bosse, T., Smit, V.T.H.B.M., Kroep, J., Nout, R.A., Nijman, H.W., de Bruyn, M., Powell, M.E., Singh, N., Kitchener, H.C., Crosbie, E., Edmondson, R., Church, D.N., Leary, A., Mileshkin, L., Pollock, P.M., MacKay, H.

“…Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the…”
Get full text

Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy by Rijkmans, E.C, Nout, R.A, Rutten, I.H.H.M, Ketelaars, M, Neelis, K.J, Laman, M.S, Coen, V.L.M.A, Gaarenstroom, K.N, Kroep, J.R, Creutzberg, C.L

“…Abstract Objective Since the Group Européen de Curiethérapie and the European Society for Radiotherapy and Oncology (GEC–ESTRO) published recommendations for…”
Get full text

Pattern of failure in IDH mutated, low grade glioma after radiotherapy – Implications for margin reduction by Jaspers, J.P.M., Méndez Romero, A., Wiggenraad, R., Compter, I., Eekers, D.B.P., Nout, R.A., van den Bent, M.

“…[Display omitted] •The pattern of failure for IDH mutated, grade 2 glioma is predominantly in – field.•Pattern of failure in this study is comparable to…”
Get full text

Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998) by Keus, R.B., Nout, R.A., Blay, J.-Y., de Jong, J.M., Hennig, I., Saran, F., Hartmann, J.T., Sunyach, M.P., Gwyther, S.J., Ouali, M., Kirkpatrick, A., Poortmans, P.M., Hogendoorn, P.C.W., van der Graaf, W.T.A.

“…To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out…”
Get full text

Acute and long-term toxicity in patients undergoing induction chemotherapy followed by thermoradiotherapy for advanced cervical cancer by Gao, X. S., Boere, I. A., van Beekhuizen, H. J., Franckena, M., Nout, R., Kruip, M. J. H. A., Kulawska, M. D., van Doorn, H. C.

“…To determine rates of vascular toxicity, acute kidney injury (AKI), chronic kidney disease (CKD) and survival in high-risk cervical cancer patients treated…”
Get full text

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients by van Meir, H., Nout, R. A., Welters, M. J. P., Loof, N. M., de Kam, M. L., van Ham, J. J., Samuels, S., Kenter, G. G., Cohen, A. F., Melief, C. J. M., Burggraaf, J., van Poelgeest, M. I. E., van der Burg, S. H.

“…New treatments based on combinations of standard therapeutic modalities and immunotherapy are of potential use, but require a profound understanding of immune…”
Get full text

Dosimetric impact of bone marrow sparing for robustly optimized IMPT for locally advanced cervical cancer by Kuipers, S.C., Godart, J., Corbeau, A., Breedveld, S., Mens, J.W.M., de Boer, S.M., Nout, R.A., Hoogeman, M.S.

“…•For robustly optimized intensity modulated proton therapy (IMPT), the bone marrow dose is reduced below clinical dose constraints for most locally advanced…”
Get full text

569 speaker TECHNOLOGICAL DEVELOPMENTS AND TRANSLATIONAL RESEARCH IN ENDOMETRIAL CANCER TREATMENT: MOLECULAR DATA AND IMAGE GUIDANCE by Nout, R

Get full text

SP-0205: Image guided brachytherapy in vaginal cancer by Fokdal, L.U, Nout, R

Get full text

Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians by Kunneman, M, Pieterse, A H, Stiggelbout, A M, Nout, R A, Kamps, M, Lutgens, L C H W, Paulissen, J, Mattheussens, O J A, Kruitwagen, R F P M, Creutzberg, C L

“…Background: Vaginal brachytherapy (VBT) in high–intermediate-risk endometrial cancer (EC) provides a significant reduction in the risk of local cancer…”
Get full text

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer by de Boer, S.M., Wortman, B.G., Bosse, T., Powell, M.E., Singh, N., Hollema, H., Wilson, G., Chowdhury, M.N., Mileshkin, L., Pyman, J., Katsaros, D., Carinelli, S., Fyles, A., McLachlin, C.M., Haie-Meder, C., Duvillard, P., Nout, R.A., Verhoeven-Adema, K.W., Putter, H., Creutzberg, C.L., Smit, V.T.H.B.M.

“…In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and…”
Get full text

Increasing global accessibility to high-level treatments for cervical cancers by Chargari, C., Arbyn, M., Leary, A., Abu-Rustum, N.R., Basu, P., Bray, F., Chopra, S., Nout, R., Tanderup, K., Viswanathan, A.N., Zacharopoulou, C., Soria, J.C., Deutsch, E., Gouy, S., Morice, P.

“…Human papillomaviruses (HPV)-related gynecological cancers are a major health care issue, and a leading cause of cancer death in low- and middle-income…”
Get full text

Mung Bean: Technological and Nutritional Potential by Dahiya, P. K, Linnemann, A. R, Van Boekel, M. A. J. S, Khetarpaul, N, Grewal, R. B, Nout, M. J. R

“…Mung bean (Vigna radiata (L.) R. Wilczek) has been intensively researched; scattered data are available on various properties. Data on physical, chemical, food…”
Get full text

Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and Obstetrics 2009 stage IB1-IIA) after neoadjuvant chemotherapy by Tesfai, Freweini Martha, Kroep, Judith R, Gaarenstroom, Katja, De Kroon, Cor, Van Loenhout, Rhiannon, Smit, Vincent, Trimbos, Baptist, Nout, R A, van Poelgeest, M I E, Beltman, Jogchum Jan

“…To assess the feasibility, safety, oncological, and obstetric outcomes in patients with cervical tumors >2 cm treated with neoadjuvant chemotherapy in…”
Get more information